Our research in response to the global pandemic

Until a vaccine is available, there is an immediate need for medicines that can prevent life-threatening complications of COVID-19.


Identifying a potential coronavirus treatment using our Knowledge Graph

1-2 February 2020

Using our AI tools and biomedical knowledge graph we identified baricitinib as a potential treatment to inhibit viral infection.

4 February 2020

Our research was published in The Lancet and we signed the Wellcome Trust pledge to share our research in response to the emerging global health crisis
Read more

28 February 2020

We published a second paper which indicated that baricitinib reduces endocytosis and the body’s hyperinflammatory response to the virus, thus potentially reducing patient mortality.
Read more

10 April 2020

Eli Lilly (who owns baricitinib) announces that baricitinib will enter a randomised-control trial with the US National Institute of Allergy and Infectious Diseases (NIAID).
Read more

15 June 2020

Eli Lilly announced that they will commence an additional phase 3 clinical trial to evaluate the efficacy and safety of baricitinib to treat COVID-19.

26 June 2020

Further experimental data supporting our AI-derived hypothesis and early results from clinical testing were published in the European Molecular Biology Organization Molecular Medicine Journal. This research was conducted in partnership with Eli Lilly.
Read more

14 September 2020

Positive data released from the NIAID’s randomised-control trial showed that baricitinib in combination with remdesivir reduces the recovery time in hospitalised patients with COVID-19, validating our AI-derived hypothesis.
Read more

If you would like further information, please contact our press team.